Fragile X syndrome is the most frequent cause of intellectual disability in males, affecting 1 out of 3600 boys born. For the first time, researchers at Whitehead Institute have restored activity to the fragile X syndrome gene in affected neurons using a modified CRISPR/Cas9 system they developed that removes the methylation—the molecular tags that keep the mutant gene shut off—suggesting that this method may prove to be a useful paradigm for targeting diseases caused by abnormal methylation.
Research by the lab of Whitehead Institute Founding Member Rudolf Jaenisch, which is described online this week in the journal Cell, is the first direct evidence that removing the methylation from a specific segment within the FMR1 locus can reactivate the gene and rescue fragile X syndrome neurons.
The FMR1 gene sequence includes a series of three nucleotide (CGG) repeats, and the length of these repeats determines whether or not a person will develop fragile X syndrome: A normal version of the gene contains anywhere from 5-55 CGG repeats; versions with 56-200 repeats are considered to be at a higher risk of generating some of the syndrome’s symptoms; and those versions with more than 200 repeats will produce fragile X syndrome.
Until now, the mechanism linking the excessive repeats in FMR1 to fragile X syndrome was not well understood. But Shawn Liu, a postdoctoral researcher in Jaenisch’s lab and first author of the Cellstudy, and others thought that the methylation blanketing those nucleotide repeats might play an important role in shutting down the gene’s expression.
In order to test this hypothesis, Liu removed the methylation tags from the FMR1 repeats using a CRISPR/Cas9-based technique recently developed by him and Hao Wu, a former postdoctoral researcher in the Jaenisch lab. This technique can either add or delete methylation tags from specific stretches of DNA. Removal of the tags revived the FMR1 gene’s expression to the level of the normal gene.
“These results are quite surprising—this work produced almost a full restoration of wild type expression levels of the FMR1 gene,” says Jaenisch, who is a professor of biology at Massachusetts Institute of Technology and the senior author on the study. “Often when scientists test therapeutic interventions, they only achieve partial restoration, so these results are substantial.”
The reactivated FMR1 gene rescues neurons derived from fragile X syndrome induced pluripotent stem (iPS) cells, reversing the abnormal electrical activity associated with the syndrome. When rescued neurons were engrafted into the brains of mice, the FMR1 gene remained active in the neurons for at least three months, suggesting that the corrected methylation may be sustainable in the animal.
“We showed that this disorder is reversible at the neuron level,” says Liu. “When we removed methylation of CGG repeats in the neurons derived from fragile X syndrome iPS cells, we achieved full activation of FMR1.”
The CRISPR/Cas-9-based technique may also prove useful for other diseases caused by abnormal methylation including facioscapulohumeral muscular dystrophy and imprinting diseases.
“This work validates the approach of targeting the methylation on genes, and it will be a paradigm for scientists to follow this approach for other diseases,” says Jaenisch.
The Latest on: Fragile X syndrome
- Embracing life with 2 children who are 'predictably unpredictable' on December 18, 2018 at 3:04 am
She promised to set up the mats in the living room for a dance party soon. Tenzin and Elliot have Fragile X syndrome. It's a genetic condition that causes a range of developmental problems. It's often ... […]
- Oxidative Stress Assay Market- Segmentation Detailed Study with Forecast to 2023 on December 17, 2018 at 11:24 am
fragile X syndrome, chronic fatigue syndrome, atherosclerosis, heart and blood vessel disorders, cardiovascular disease, inflammatory diseases and others.Oxidative stress assay is a method for ... […]
- Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome on December 13, 2018 at 10:28 am
Zynerba Pharmaceuticals (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is reporting new 12 ... […]
- The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen on December 13, 2018 at 3:56 am
Xolair is administered via injection every two or four weeks. Zynerba's Cannabinoid Drug Produces Sustained Improvement In Fragile X Syndrome Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported new 12 ... […]
- AGTC Slumps After-hrs, NBIX Fails To Strike GOLD, IDRA To Report Data On Dec.14 on December 12, 2018 at 9:11 pm
In the phase II trial of ZYN002 in children and adolescents with Fragile X Syndrome, dubbed FAB-C, patients experienced a 77% improvement in aberrant behaviors associated with social avoidance compare... […]
- Global Fragile X Syndrome Market Trending Technologies, Developments, Key Players and Forecast to 2025 on November 25, 2018 at 10:42 pm
Global Fragile X Syndrome Market 2018 By Key Vendors - Aelis Farma SAS, Alcobra Ltd, AMO Pharma Limited, Confluence Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Marinus Pharm... […]
- Fragile X Syndrome - 2018 Pipeline Insight Report - ResearchAndMarkets.com on October 17, 2018 at 4:35 am
The "Fragile X Syndrome - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. This report offers a comprehensive insight of the pipeline (under development) the... […]
- US Fragile X Syndrome Market and Competitive Landscape - 2018 - ResearchAndMarkets.com on October 10, 2018 at 7:10 am
DUBLIN--(BUSINESS WIRE)--The "US Fragile X Syndrome Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. US Fragile X Syndrome Market and Competitive La... […]
- Fragile X syndrome on October 8, 2018 at 5:00 pm
I got a call from my doctor this morning saying that I am a carrier for fragile x syndrome. and there’s a 50/50 chance that I will give this disease to a son if I am having one. I’m 14 weeks and 5 day... […]
- What You Need to Know about Fragile X Syndrome on September 20, 2018 at 12:46 pm
Fragile X syndrome affects approximately 1 in 4,000 males and 1 in 6,000 females born in the United States. The genetic disorder is found in all ethnic groups. Experts estimate that around 1 in 800 ma... […]
via Google News and Bing News